MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
November 03 2008 - 7:30AM
PR Newswire (US)
GERMANTOWN, Md., Nov. 3 /PRNewswire-FirstCall/ -- MiddleBrook
Pharmaceuticals, Inc. (NASDAQ:MBRK), a pharmaceutical company
focused on developing and commercializing novel anti-infective
products, today announced that it has retained national account
firm VCG & Associates. VCG & Associates will serve as
MiddleBrook's strategic and tactical managed care partner,
assisting in product pricing and reimbursement, contract
administration, national account management and government account
coverage. President and CEO John Thievon said, "VCG &
Associates has mirrored MiddleBrook's excitement regarding the
upcoming launch of MOXATAG, the first and only FDA-approved
once-daily amoxicillin, and it's clear they have a strong
commitment to the launch's success." Thievon continued, "While our
professional field force will champion the advantages of MOXATAG
over currently available amoxicillin therapies with healthcare
practitioners across the nation, VCG & Associates will lead the
charge to inform and engage managed care organizations, as well as
government and non-retail outlets throughout the country. This is
an exciting alliance for MiddleBrook." ABOUT MOXATAG(TM): MOXATAG
(extended-release amoxicillin) 775mg tablets are a once-a-day
extended-release formulation of amoxicillin for oral administration
consisting of three components: one immediate-release component and
two delayed-release components. The three components are combined
in a specific ratio to prolong the release of amoxicillin from
MOXATAG compared to immediate-release amoxicillin. MOXATAG is
intended to provide a lower treatment dose, once- daily alternative
to currently approved penicillin and amoxicillin regimens for the
treatment of adults and pediatric patients 12 years and older with
tonsillitis and/or pharyngitis. About Middlebrook Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (NASDAQ:MBRK) is a pharmaceutical
company focused on the development and commercialization of
anti-infective drug products that fulfill substantial unmet medical
needs in the treatment of infectious disease. The Company is
developing anti-infective drugs based on its novel biological
finding that bacteria exposed to antibiotics in pulses are killed
more efficiently than those under standard treatment regimens.
Based on this finding, MiddleBrook has developed a proprietary,
once-a-day pulsatile delivery technology called PULSYS(R). The
Company currently markets the KEFLEX(R) brand of cephalexin and has
received regulatory approval for MOXATAG(TM) - the first and only
once-daily amoxicillin product approved for marketing in the U.S.
For more information about MiddleBrook, please visit
http://www.middlebrookpharma.com/. About VCG & Associates: VCG
& Associates, Inc. is an independent strategic marketing and
contract national account organization specializing in the
commercialization of pharmaceutical, biotech, and medical device
products. VCG & Associates has successfully brought together a
select combination of industry experts to cover the spectrum of
product entry into the US market. The company's core area of
expertise can be divided into two categories; strategic planning
and active field execution. Strategic planning activities include
market research, pricing and reimbursement, strategic planning,
commercialization planning, and launch plans. Field execution
activities include: trade support, contracting administration,
national account management, and government account coverage. This
announcement contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934 and
Section 27A of the Securities Act of 1933, that involve risks and
uncertainties. In some cases, forward-looking statements are
identified by words such as "believe," "anticipate," "expect,"
"intend," "plan," "potential," "estimate," "will," "may,"
"predict," "should," "could," "would" and similar expressions. You
should not place undue reliance on these forward-looking
statements, which speak only as of the date of this announcement.
All of these forward-looking statements are based on information
available to us at this time. Actual results could differ from
those projected in these forward-looking statements as a result of
many factors, including those identified in the sections titled
"Risk Factors," in our Registration Statement on Form S-3 as filed
with the Securities and Exchange Commission on October 17, 2008,
and in our "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in our Annual
Report on Form 10-K for the year ended Dec. 31, 2007 and in similar
disclosures made by us from time to time in our other filings with
the Securities and Exchange Commission. We undertake no obligation
to update forward-looking statements, whether as a result of new
information, future events or otherwise. You are advised, however,
to consult any further disclosures we make on related subjects in
our filings with the Securities and Exchange Commission.
MiddleBrook, MiddleBrook Pharmaceuticals, Inc., PULSYS, MOXATAG and
Keflex are our trademarks and have been registered in the U.S.
Patent and Trademark Office or are the subject of pending U.S.
trademark applications. Each of the other trademarks, tradenames or
services marks appearing in this document belongs to its respective
holder. DATASOURCE: MiddleBrook Pharmaceuticals, Inc. CONTACT:
Investor/Media: Faith Pomeroy-Ward, +1-301-944-6585 of MiddleBrook
Pharmaceuticals, Inc. Web Site: http://www.middlebrookpharma.com/
Copyright
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Aug 2023 to Aug 2024